Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of updated 5-year results from the EV-103 trial (NCT03288545), which assessed enfortumab vedotin (EV) plus pembrolizumab in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (la/mUC). With a manageable safety profile, the combination showed promising efficacy, and these results affirm EV and pembrolizumab as a durable first-line therapy for la/mUC. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
